Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/10105395241286446 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Snapshot of the Tuberculosis situation in Mongolia: in Association with COVID-19.
Asia Pac J Public Health
November 2024
Department of Public Health, Graduate School of Medicine, Gunma University, Maebashi, Japan.
Latent Tuberculosis Infection Management in Solid Organ Transplantation Recipients: A National Snapshot.
Thorac Res Pract
May 2024
Department of Infectious Diseases and Clinical Microbiology, Mersin University Faculty of Medicine, Mersin, Turkey.
Article Synopsis
- Latent tuberculosis infection (LTBI) screening is essential for solid organ transplant (SOT) recipients, but many centers in Turkey are not adequately performing these screenings.
- In a study involving 766 SOT patients, 46.9% tested positive for LTBI, but only about half of those treated were registered, and there was a low completion rate of treatment.
- The findings highlight the need for better TB risk assessment and adherence to national guidelines to improve pre-transplant care for SOT recipients in Turkey.
Background: Current tuberculosis treatment regimens primarily rely on phenotypic drug susceptibility testing and rapid molecular assays. Although whole-genome sequencing (WGS) offers a promising alternative, disagreements between phenotypic and molecular testing methods remain. In this retrospective study, we compared the phenotypic and WGS-predicted drug resistance profiles of paired isolates with small genetic distances (≤10 single nucleotide variants) obtained from patients with longitudinal single-episode or recurrent tuberculosis.
View Article and Find Full Text PDFSwitch to long-acting cabotegravir and rilpivirine in virologically suppressed adults with HIV in Africa (CARES): week 48 results from a randomised, multicentre, open-label, non-inferiority trial.
Lancet Infect Dis
October 2024
London School of Hygiene & Tropical Medicine, London, UK; Infectious Diseases Translational Research Programme and Yong Loo Lin School of Medicine, National University of Singapore, Singapore. Electronic address:
Background: Long-acting injectable cabotegravir and rilpivirine is licensed for individualised treatment of HIV-1 infection in resource-rich settings. Additional evidence is required to support use in African treatment programmes where demographic factors, viral subtypes, previous treatment, and delivery and monitoring approaches differ. The aim of this study was to determine whether switching to long-acting therapy with injections every 8 weeks is non-inferior to daily oral therapy in Africa.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!